Professor of Pediatrics, Johns Hopkins University School of Medicine; Director of Pediatric Pulmonology
Pediatric Pulmonology
Dr. Pamela Zeitlin, MD
|
|
Give Review
Pamela Zeitlin is an expert in the field of Pediatric Pulmonology. She went to medical school at Yale University School of Medicine. Yale University School of Medicine is a one of the best medicals schools. Yale University School of Medicine is ranked 7/57 in Research/PrimaryCare. She received 3 awards: "America's Top Doctors", "Top Doctors:Baltimore Area" and "Top Doctors:Washington-Baltimore". Pamela Zeitlin is also published. She has 98 publications published. The lastest publication: "Therapies directed at the basic defect in cystic fibrosis.'
Publications
- Direct interactions between ENaC gamma subunit and ClCN2 in Cystic fibrosis epithelial cells.
- Ataluren for the treatment of nonsense-mutation Cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial.
- Interference with ubiquitination in CFTR modifies stability of core glycosylated and cell surface pools.
- Dual activation of CFTR and CLCN2 by lubiprostone in murine nasal epithelia.
- Effect of adeno-associated virus-specific immunoglobulin G in human amniotic fluid on gene transfer.
- Modulation of Sp1 and Sp3 in lung epithelial cells regulates ClC-2 chloride channel expression.
- Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult Cystic fibrosis patients: ...
- A multicenter study of the effect of solution temperature on nasal potential difference measurements.
- Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in Cystic fibrosis.
- Protein processing and degradation in pulmonary health and disease.
- Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins.
- Emerging drug treatments for Cystic fibrosis.
- A phase I trial of intranasal Moli1901 for Cystic fibrosis.
- Repeated adeno-associated virus serotype 2 aerosol-mediated Cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with Cystic fibrosis: a mult...
- Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter Cystic fibrosis clinical trials.
- Modulation of deltaF508 Cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids.
- Can curcumin cure Cystic fibrosis?
- Evaluation of exposure and health care worker response to nebulized administration of tgAAVCF to patients with Cystic fibrosis.
- Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate Cystic fibrosis lung disease.
- Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate...
- Down-regulation of IL-8 expression in human airway epithelial cells through helper-dependent adenoviral-mediated RNA interference.
- Correlation between DNA transfer and Cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy.
- Positive expiratory pressure changes aerosol distribution in patients with Cystic fibrosis.
- Acidic pH hyperpolarizes nasal potential difference.
- Serum proteomic signature for Cystic fibrosis using an antibody microarray platform.
- Regulation of the ClC-2 lung epithelial chloride channel by glycosylation of SP1.
- Pharmacoproteomics of 4-phenylbutyrate-treated IB3-1 Cystic fibrosis bronchial epithelial cells.
- Respiratory epithelial gene expression in patients with mild and severe Cystic fibrosis lung disease.
- Selective inhibition of endoplasmic reticulum-associated degradation rescues DeltaF508-Cystic fibrosis transmembrane regulator and suppresses interleukin-8 levels: the...
- Membrane-associated heparan sulfate is not required for rAAV-2 infection of human respiratory epithelia.
- De novo biosynthetic profiling of high abundance proteins in Cystic fibrosis lung epithelial cells.
- Is it go or NO go for S-nitrosylation modification-based therapies of Cystic fibrosis transmembrane regulator trafficking?
- Variants in mannose-binding lectin and tumour necrosis factor alpha affect survival in Cystic fibrosis.
- Cystic fibrosis transmembrane regulator protein mutations: ''class'' opportunity for novel drug innovation.
- Levofloxacin pharmacokinetics in adult Cystic fibrosis.
- Duration of treatment effect after tobramycin solution for inhalation in young children with Cystic fibrosis.
- Patients with mutations in Gsalpha have reduced activation of a downstream target in epithelial tissues due to haploinsufficiency.
- Repeated aerosolized AAV-CFTR for treatment of Cystic fibrosis: a randomized placebo-controlled phase 2B trial.
- CHOP transcription factor mediates IL-8 signaling in Cystic fibrosis bronchial epithelial cells.
- Pulmonary function in adolescents with ataxia telangiectasia.
- Chemical rescue of deltaF508-CFTR mimics genetic repair in Cystic fibrosis bronchial epithelial cells.
- Dietary supplement use in pediatric patients with Cystic fibrosis.
- Atypical Cystic fibrosis and CFTR-related diseases.
- Cystic fibrosis presenting as recurrent pancreatitis in a young child with a normal sweat test and pancreas divisum: a case report.
- Current treatment recommendations for correcting vitamin D deficiency in pediatric patients with Cystic fibrosis are inadequate.
- Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in Cystic fibrosis mice.
- Spiperone, identified through compound screening, activates calcium-dependent chloride secretion in the airway.
- Cystic fibrosis and estrogens: a perfect storm.
- The penetration of fresh undiluted sputum expectorated by Cystic fibrosis patients by non-adhesive polymer nanoparticles.
- Proteome of synaptosome-associated proteins in spinal cord dorsal horn after peripheral nerve injury.
- CFTR is a negative regulator of NFkappaB mediated innate immune response.
- Description of a standardized nutrition classification plan and its relation to nutritional outcomes in children with Cystic fibrosis.
- Pseudomonas aeruginosa: can studies in engineered cells tell us why is it such a problem in people with Cystic fibrosis? Focus on "Cystic fibrosis transmembrane conduc...
- Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrier.
- NHLBI training workshop report: The vanishing pediatric pulmonary investigator and recommendations for recovery.
- Transient effectiveness of vitamin D2 therapy in pediatric Cystic fibrosis patients.
- Ubiquitin C-terminal hydrolase-L1 protects Cystic fibrosis transmembrane conductance regulator from early stages of proteasomal degradation.
- Elevated serum IL-8 levels in ataxia telangiectasia.
- Applications of proteomic technologies for understanding the premature proteolysis of CFTR.
- Protein microarray platforms for clinical proteomics.
- Cystic fibrosis and sinusitis in children: outcomes and socioeconomic status.
- N-acetylcysteine enhances Cystic fibrosis sputum penetration and airway gene transfer by highly compacted DNA nanoparticles.
- Antibody microarrays: analysis of Cystic fibrosis.
- ClC-5: ontogeny of an alternative chloride channel in respiratory epithelia.
- cis-Acting elements within CFTR 5''-flanking DNA are not sufficient to decrease gene expression in response to phorbol ester.
- Evidence of CFTR function in Cystic fibrosis after systemic administration of 4-phenylbutyrate.
- Variant Cystic fibrosis phenotypes in the absence of CFTR mutations.
- Therapeutic approaches to repair defects in deltaF508 CFTR folding and cellular targeting.
- Significant microbiological effect of inhaled tobramycin in young children with Cystic fibrosis.
- Safety of aerosolized INS 365 in patients with mild to moderate Cystic fibrosis: results of a phase I multi-center study.
- Cell surface distribution and intracellular fate of asialoglycoproteins: a morphological and biochemical study of isolated rat hepatocytes and monolayer cultures.
- Stable in vivo expression of the Cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector.
- A1 receptor antagonist 8-cyclopentyl-1,3-dipropylxanthine selectively activates chloride efflux from human epithelial and mouse fibroblast cell lines expressing the cy...
- Cystic fibrosis gene and protein expression during fetal lung development.
- Expression of the Cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter.
- An immortalized Cystic fibrosis tracheal epithelial cell line homozygous for the delta F508 CFTR mutation.
- CIC-2: a developmentally dependent chloride channel expressed in the fetal lung and downregulated after birth.
- Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration.
- "Bronchitis" obliterans and prolonged transient hypogammaglobulinemia in a child.
- Alveolar stem cell transduction by an adeno-associated viral vector.
- A short CIC-2 mRNA transcript is produced by exon skipping.
- Gestational and tissue-specific regulation of C1C-2 chloride channel expression.
- CFTR gene transduction in neonatal rabbits using an adeno-associated virus (AAV) vector.
- Alternative mRNA splice variants of the rat ClC-2 chloride channel gene are expressed in lung: genomic sequence and organization of ClC-2.
- Prognosis in Cystic fibrosis.
- In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in Cystic fibrosis epithelial cells containing delta F508-CFTR.
- A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous Cystic fibrosis patients: partial restoration of nasal epithelial CFTR function.
- Analysis of ClC-2 channels as an alternative pathway for chloride conduction in Cystic fibrosis airway cells.
- Use of protein repair therapy in the treatment of Cystic fibrosis.
- Therapies directed at the basic defect in Cystic fibrosis.
- Novel pharmacologic therapies for Cystic fibrosis.
- Keratinocyte growth factor stimulates CLC-2 expression in primary fetal rat distal lung epithelial cells.
- Perinatal regulation of the ClC-2 chloride channel in lung is mediated by Sp1 and Sp3.
- Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR.
- Pharmacologic restoration of delta F508 CFTR-mediated chloride current.
- pH-regulated chloride secretion in fetal lung epithelia.
- Cystic fibrosis gene therapy trials and tribulations.
Schools
Yale University
Johns Hopkins Hospital
Conditions Treated
- Asthma
- Bronchitis
- Cystic Fibrosis
Doctors Specialties
- Pediatric Pulmonology
Accepted Insurances
Awards
- America's Top Doctors
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
Education
-
Johns Hopkins University -
Yale University School of Medicine
Hospital
-
Johns Hopkins Hospital -
Johns Hopkins Bayview Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Anna Fishbein, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric D. McCollum, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Beryl J. Rosenstein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria Cecilia S. Melendres, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Laura Sterni, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph M. Collaco, MD |
|
|
Dr. Catherine M. Bonuccelli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Preston W. Campbell III, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anayansi Lasso-Pirot, MD |
|
|
Dr. Samantha L. Jackson, MD |
|
|
Lisa M. Bell, CRNP |
|
|
Dr. Bridget D. Stuart, MD |